Lumos Pharma to Participate in the Cantor Neurology & Psychiatry Conference

September 26, 2022

https://www.globenewswire.com/news-release/2022/09/26/2522850/15114/en/Lumos-Pharma-to-Participate-in-the-Cantor-Neurology-Psychiatry-Conference.html

AUSTIN, Texas, Sept. 26, 2022 (GLOBE NEWSWIRE) — Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing a novel oral therapeutic candidate, LUM-201, through Phase 2 clinical trials for Pediatric Growth Hormone Deficiency (PGHD), announced that Lumos Pharma management will participate in a panel discussion and host one-on-one meetings at the Cantor Neurology & Psychiatry Conference in October.

Read more at globenewswire.com

Related news for (LUMO)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.